Literature DB >> 24115035

Adenosine monophosphate-activated protein kinase-α2 deficiency promotes vascular smooth muscle cell migration via S-phase kinase-associated protein 2 upregulation and E-cadherin downregulation.

Ping Song1, Yanhong Zhou, Kathleen A Coughlan, Xiaoyan Dai, Hairong Xu, Benoit Viollet, Ming-Hui Zou.   

Abstract

OBJECTIVE: Abnormal proliferation and migration of vascular smooth muscle cells (VSMCs) are critical events in the progression of several vasculopathologies. Adenosine monophosphate-activated protein kinase (AMPK) has been shown to play a pivotal role in cellular proliferation and migration. However, the roles of AMPK in VSMC migration and its underlying molecular mechanisms remain elusive. APPROACH AND
RESULTS: VSMC migration and the neointima formation were studied in cultured mouse VSMCs or in carotid artery ligation of wild-type C57BL/6J mice, AMPKα2, AMPKα1 homozygous-deficient (AMPKα2(-/-), AMPKα1(-/-)) mice. Deletion of AMPKα2, but not AMPKα1, led to increased phosphorylation of both IкB kinase α and its downstream target nuclear factor кB2/p100 at serine 866/870. Consequently, phosphor-p100 at S866/870 bound with E3 ubiquitin ligase β-transducin repeat-containing protein resulting in the proteolytic processing of the p100 precursor and nuclear factor кB2/p52 induction. Interestingly, acetylation of histone H3 at lysine 56 mediated by histone deacetylase-3 reduction was enhanced significantly in AMPKα2(-/-) VSMCs compared with wild-type or AMPKα1(-/-) VSMCs. Moreover, the augmented association of p52/acetylation of histone H3 at lysine 56 with the promoter of ubiquitin E3 ligase, S-phase kinase-associated protein 2, was shown in AMPKα2(-/-) VSMCs by chromatin immunoprecipitation assay. Furthermore, AMPKα2 deletion caused S-phase kinase-associated protein 2-mediated E-cadherin downregulation. S-Phase kinase-associated protein 2 siRNA abolished the increased migration of AMPKα2(-/-) VSMCs via E-cadherin upregulation. Finally, neointima formation after ligation of carotid artery was increased in AMPKα2(-/-), but not AMPKα1(-/-), mice.
CONCLUSIONS: We conclude that deletion of AMPKα2 causes aberrant VSMC migration with accelerated neointima formation in vivo.

Entities:  

Keywords:  AMP-activated protein kinase kinase; S-phase kinase–associated proteins; cadherins; cell movement; vascular smooth muscle cell

Mesh:

Substances:

Year:  2013        PMID: 24115035      PMCID: PMC3910301          DOI: 10.1161/ATVBAHA.113.301869

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  47 in total

1.  Acetylation-dependent regulation of Skp2 function.

Authors:  Hiroyuki Inuzuka; Daming Gao; Lydia W S Finley; Wen Yang; Lixin Wan; Hidefumi Fukushima; Y Rebecca Chin; Bo Zhai; Shavali Shaik; Alan W Lau; Zhiwei Wang; Steven P Gygi; Keiko Nakayama; Julie Teruya-Feldstein; Alex Toker; Marcia C Haigis; Pier Paolo Pandolfi; Wenyi Wei
Journal:  Cell       Date:  2012-07-06       Impact factor: 41.582

2.  Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles.

Authors:  N E Tawa; R Odessey; A L Goldberg
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

Review 3.  Smooth muscle migration in atherosclerosis and restenosis.

Authors:  S M Schwartz
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

4.  Remodeling with neointima formation in the mouse carotid artery after cessation of blood flow.

Authors:  A Kumar; V Lindner
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-10       Impact factor: 8.311

5.  HDAC5 is a novel injury-regulated tubulin deacetylase controlling axon regeneration.

Authors:  Yongcheol Cho; Valeria Cavalli
Journal:  EMBO J       Date:  2012-06-12       Impact factor: 11.598

6.  Induction of p100 processing by NF-kappaB-inducing kinase involves docking IkappaB kinase alpha (IKKalpha) to p100 and IKKalpha-mediated phosphorylation.

Authors:  Gutian Xiao; Abraham Fong; Shao-Cong Sun
Journal:  J Biol Chem       Date:  2004-05-11       Impact factor: 5.157

7.  AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury.

Authors:  Joshua D Stone; Avinash Narine; Patti R Shaver; Jonathan C Fox; Jackson R Vuncannon; David A Tulis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-11-30       Impact factor: 4.733

8.  AMP-activated protein kinase inhibits angiotensin II-stimulated vascular smooth muscle cell proliferation.

Authors:  Daisuke Nagata; Ryo Takeda; Masataka Sata; Hiroshi Satonaka; Etsu Suzuki; Tetsuo Nagano; Yasunobu Hirata
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

9.  Vinpocetine suppresses pathological vascular remodeling by inhibiting vascular smooth muscle cell proliferation and migration.

Authors:  Yujun Cai; Walter E Knight; Shujie Guo; Jian-Dong Li; Peter A Knight; Chen Yan
Journal:  J Pharmacol Exp Ther       Date:  2012-08-22       Impact factor: 4.030

10.  Amplification and overexpression of SKP2 are associated with metastasis of non-small-cell lung cancers to lymph nodes.

Authors:  Sana Yokoi; Kohichiroh Yasui; Miki Mori; Toshihiko Iizasa; Takehiko Fujisawa; Johji Inazawa
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

View more
  10 in total

1.  AMP-Activated Protein Kinase Alpha 2 Deletion Induces VSMC Phenotypic Switching and Reduces Features of Atherosclerotic Plaque Stability.

Authors:  Ye Ding; Miao Zhang; Wencheng Zhang; Qiulun Lu; Zhejun Cai; Ping Song; Imoh Sunday Okon; Lei Xiao; Ming-Hui Zou
Journal:  Circ Res       Date:  2016-07-20       Impact factor: 17.367

2.  Time and flow-dependent changes in the p27(kip1) gene network drive maladaptive vascular remodeling.

Authors:  Kenneth M DeSart; Khayree Butler; Kerri A O'Malley; Zhihua Jiang; Scott A Berceli
Journal:  J Vasc Surg       Date:  2014-06-20       Impact factor: 4.268

Review 3.  Minireview: hey U(PS): metabolic and proteolytic homeostasis linked via AMPK and the ubiquitin proteasome system.

Authors:  Sarah M Ronnebaum; Cam Patterson; Jonathan C Schisler
Journal:  Mol Endocrinol       Date:  2014-08-06

4.  Redox regulation of endothelial cell fate.

Authors:  Ping Song; Ming-Hui Zou
Journal:  Cell Mol Life Sci       Date:  2014-03-15       Impact factor: 9.261

5.  Pioglitazone Attenuates Injury-Induced Neointima Formation in Mouse Femoral Artery Partially through the Activation of AMP-Activated Protein Kinase.

Authors:  Islam Osman; Arwa Fairaq; Lakshman Segar
Journal:  Pharmacology       Date:  2017-05-09       Impact factor: 2.547

Review 6.  Functional characterization of AMP-activated protein kinase signaling in tumorigenesis.

Authors:  Ji Cheng; Tao Zhang; Hongbin Ji; Kaixiong Tao; Jianping Guo; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2016-09-25

Review 7.  AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System.

Authors:  Ian P Salt; D Grahame Hardie
Journal:  Circ Res       Date:  2017-05-26       Impact factor: 17.367

8.  Deletion of Ulk1 inhibits neointima formation by enhancing KAT2A/GCN5-mediated acetylation of TUBA/α-tubulin in vivo.

Authors:  Changhan Ouyang; Jian Li; Xiaoxu Zheng; Jing Mu; Gloria Torres; Qilong Wang; Ming-Hui Zou; Zhonglin Xie
Journal:  Autophagy       Date:  2021-05-14       Impact factor: 13.391

9.  Activation of AMPKα2 in adipocytes is essential for nicotine-induced insulin resistance in vivo.

Authors:  Yue Wu; Ping Song; Wencheng Zhang; Junhui Liu; Xiaoyan Dai; Zhaoyu Liu; Qiulun Lu; Changhan Ouyang; Zhonglin Xie; Zhengxing Zhao; Xiaozhen Zhuo; Benoit Viollet; Marc Foretz; Jiliang Wu; Zuyi Yuan; Ming-Hui Zou
Journal:  Nat Med       Date:  2015-03-23       Impact factor: 53.440

10.  Tertiary butylhydroquinone alleviated liver steatosis and increased cell survival via β-arrestin-2/PI3K/AKT pathway.

Authors:  Tian-Tian Zhu; Chao-Nan Zhu; Yue Qiu; Qian-Shuai Li; Xin Yu; Guo-Jie Hao; Ping Song; Jian Xu; Peng Li; Ya-Ling Yin
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.